- Home
- STWD vs PRAX Comparison
STWD vs PRAX Comparison
Compare STWD & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STWD | PRAX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 7.2B |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STWD | PRAX |
|---|---|---|
| Price | $18.51 | $322.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $20.63 | ★ $397.85 |
| AVG Volume (30 Days) | ★ 3.9M | 566.4K |
| Earning Date | 02-26-2026 | 02-27-2026 |
| Dividend Yield | ★ 10.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $490,651,000.00 | $7,463,000.00 |
| Revenue This Year | $366.38 | N/A |
| Revenue Next Year | $12.15 | $14,827.76 |
| P/E Ratio | $17.63 | ★ N/A |
| Revenue Growth | 12.42 | ★ 364.98 |
| 52 Week Low | $16.59 | $26.70 |
| 52 Week High | $21.05 | $317.72 |
Technical Indicators
Market Signals| Indicator | STWD | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 54.61 | 67.71 |
| Support Level | $17.78 | $266.93 |
| Resistance Level | $18.59 | $306.16 |
| Average True Range (ATR) | 0.31 | 17.82 |
| MACD | 0.00 | -1.04 |
| Stochastic Oscillator | 86.98 | 85.53 |
Price Performance
Historical ComparisonAbout STWD STARWOOD PROPERTY TRUST INC. Starwood Property Trust Inc.
Starwood Property Trust Inc is an American real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans and commercial mortgage-backed securities in the U.S. and Europe. The company organizes its activities into Commercial and Residential Lending Segment, Infrastructure Lending Segment, Property Segment, and Investing & Servicing Segment. The company generates the majority of its revenue from the Commercial and Residential Lending Segment, which is engaged in originating, acquiring, financing, and managing commercial first mortgages, and non-agency residential mortgages.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.